Publication
Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
Related publications (31)
Cyrus Kazemiraad, Saeed Mohammadi
Henning Paul-Julius Stahlberg, Dongchun Ni
Freddy Radtke, Ute Koch, Nadine Fournier, Marianne Nkosi, Christelle Dubey, Mateusz Waldemar Antoszewski, Tara Kimberly Sugrue, Giovanni Ciriello
Natalia Gasilova, Laure Menin, Rita Sarkis, Maria Younes
Hilal Lashuel, Nadine Aït Bouziad, Anass Chiki, Galina Limorenko
Matteo Dal Peraro, Florence Pojer, Sandrine Madeleine Suzanne Georgeon, Maria Josefina Marcaida Lopez, Oliver Hantschel, Allan Joaquim Lamontanara, Tim Kükenshöner, Daniel Pereira Duarte, Grégory La Sala